Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

@article{Nobori1994DeletionsOT,
  title={Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers},
  author={Tsutomu Nobori and Kaoru Miura and David J. Wu and Augusto F. Lois and Kenji Takabayashi and Dennis A. Carson},
  journal={Nature},
  year={1994},
  volume={368},
  pages={753-756}
}

Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.

The deletion analyses strongly suggest that the p16 gene is a tumor-suppressor gene located in chromosome 9p21 that is involved in development of human lymphoid tumors.

Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.

The results suggest that loss of the CDK4I function may contribute to immortalization of human leukemia cells and play a causative role at least in development of human lymphocytic leukemias.

Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.

It is concluded that homozygous p16 gene deletions characterize a subset of ALL with features of aggressive disease.

Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.

Two groups of CDKIs are classified based on the structure of the proteins, including the p15, p16, and p18CDKIs, which have ankyrin repeat motifs, and the p27/Kip1 and p21 CDKI genes, which are rarely mutated in human malignancies.

Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas

It is suggested that alterations in the integrity of the human p27 gene are not common events in human breast carcinoma, despite the occurrence of two sequence variations with respect to the reported sequence.

Mutational and methylation analysis of the cyclin‐dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia

The results indicate that genetic alterations of p16 gene are rare events in patients with CLL, and the clarification of the role of p 16 gene promoter methylation in the pathogenesis and evolution of CLL needs further investigation.

Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma

Examination of the contribution of the cell cycle inhibitor genes P15, P16, and P18 to pathogenesis in a large panel of 209 cytogenetically characterized B-cell NHL tumors indicates that deletion of P15 and P16 occurs in about 15% of diffuse large- cell NHL and is not usually detected by cytogenetic analysis.

Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.

Examination of the contribution of the cell cycle inhibitor genes P15, P16, and P18 to pathogenesis in a large panel of 209 cytogenetically characterized B-cell NHL tumors indicates that deletion of P15 and P16 occurs in about 15% of diffuse large- cell NHL and is not usually detected by cytogenetic analysis.

Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.

Observations support a role for p15/p16 gene inactivation in bladder carcinogenesis and/or the promotion of cell growth in vitro and lend support to the hypothesis that homozygous deletion centred on 9p21 is a mechanism by which both p15 and p16 genes are co-inactivated.

p16 mutations/deletions are not frequent events in prostate cancer.

It is suggested that p16INK4 is a tumour-suppressor gene involved in a wide variety of human cancers, and mutation of the p16ink4 gene is not a frequent genetic alteration implicated in prostate cancer development.
...

References

SHOWING 1-10 OF 13 REFERENCES

Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.

Findings suggest that the putative tumor suppressor gene at this locus contributes to the malignant process in lung cancers, as well as other types of human cancer.

p21 is a universal inhibitor of cyclin kinases

It is found that over expression of p21 inhibits the activity of each member of the cyclin/CDK family, and this results indicate that p21 may be a universal inhibitor of cyclin kinases.

Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas.

It is confirmed that loss of DNA sequences on 9p, particularly the IFN genes, occurs at a significant frequency in gliomas, and may represent an important step in the progression of these tumors.

Homozygous deletions within human chromosome band 9p21 in melanoma.

A small critical region of 2-3 megabases on 9p21 in which a putative melanoma tumor-suppressor gene appears likely to reside is identified in which several 9p candidate genes have been eliminated because they are located outside of the homozygously deleted regions.

Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s).

Cutaneous malignant melanoma (CMM) is often familial, but the mode of inheritance and the chromosomal location of melanoma susceptibility locus are controversial. Identification of a 34-year-old

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

P16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein, and inhibits the catalytic activity of theCDK4/cyclin D enzymes.

Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.

Linkage analysis of Utah kindreds and one Texas kindred with multiple cases of cutaneous malignant melanoma provided evidence that a locus for familial melanoma susceptibility is in the chromosomal region 9p13-p22, previously implicated in homozygous deletions in melanoma tumors.

Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers.

The data suggest that MeSAdo phosphorylase deficiency is frequently found in non-small cell lung cancers and can be exploited in designing enzyme-selective chemotherapy.